NASDAQ:TBPH Theravance Biopharma - TBPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.76 -0.11 (-1.01%) (As of 01/30/2023 01:22 PM ET) Add Compare Share Share Today's Range$10.71▼$10.9350-Day Range$10.27▼$11.4452-Week Range$7.53▼$11.83Volume88,750 shsAverage Volume454,013 shsMarket Capitalization$724.86 millionP/E Ratio0.96Dividend YieldN/APrice Target$14.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Theravance Biopharma MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside36.4% Upside$14.67 Price TargetShort InterestBearish14.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 2 Articles This WeekInsider TradingSelling Shares$581,861 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.88) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector915th out of 1,049 stocksPharmaceutical Preparations Industry447th out of 514 stocks 3.2 Analyst's Opinion Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, Theravance Biopharma has a forecasted upside of 36.4% from its current price of $10.75.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.84% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently increased by 3.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TBPH. Previous Next 2.1 News and Social Media Coverage News SentimentTheravance Biopharma has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $581,861.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Theravance Biopharma is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Theravance Biopharma are expected to decrease in the coming year, from ($0.88) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is 0.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is 0.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.83. Previous Next See Top Rated MarketRank™ Stocks Here About Theravance Biopharma (NASDAQ:TBPH) StockTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by StockNews.comJanuary 9, 2023 | finance.yahoo.comTheravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key TargetsJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 25, 2022 | finance.yahoo.comShareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years agoDecember 7, 2022 | finance.yahoo.comWhy Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?November 18, 2022 | finance.yahoo.comTheravance Biopharma, Inc. Announces Preliminary Results of Tender OfferNovember 11, 2022 | finance.yahoo.comWe Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) SoonNovember 8, 2022 | seekingalpha.comTheravance Biopharma, Inc. (TBPH) Q3 2022 Earnings Call TranscriptJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 8, 2022 | finance.yahoo.comTheravance (TBPH) Q3 Loss Narrower Than Expected, Sales MissNovember 4, 2022 | msn.comA Preview Of Theravance Biopharma's EarningsNovember 2, 2022 | finance.yahoo.comAmpreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous SystemOctober 31, 2022 | finance.yahoo.comTheravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022October 25, 2022 | finance.yahoo.comTheravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous SystemSeptember 29, 2022 | finanznachrichten.deTheravance Biopharma, Inc.: Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary SharesSeptember 28, 2022 | nasdaq.comTheravance Biopharma Announces Modified Dutch Auction Tender Offer - Quick FactsSeptember 28, 2022 | marketwatch.comTheravance Biopharma Sets $95 Million Stock Tender Offer >TBPHSeptember 28, 2022 | finance.yahoo.comTheravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary SharesSeptember 21, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)September 20, 2022 | finance.yahoo.comCompany News for Sep 20, 2022September 19, 2022 | msn.comHere's Why Theravance Biopharma Shares Are MovingSeptember 19, 2022 | finance.yahoo.comTheravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire HoldingsSeptember 19, 2022 | markets.businessinsider.comTheravance Biopharma Rises 6% On News Of Share BuybackSeptember 19, 2022 | markets.businessinsider.comTheravance To Buy Back $250 Mln Of SharesSeptember 8, 2022 | finance.yahoo.comCatalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?August 16, 2022 | nasdaq.comBroker Revenue Forecasts For Theravance Biopharma, Inc. (NASDAQ:TBPH) Are Surging HigherAugust 14, 2022 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Theravance Biopharma, Inc. (NASDAQ:TBPH) RevenuesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Company Calendar Last Earnings11/07/2022Today1/30/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.67 High Stock Price Forecast$19.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+36.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$11.26 Trailing P/E Ratio0.96 Forward P/E RatioN/A P/E GrowthN/ANet Income$-199,430,000.00 Net Margins1,646.84% Pretax Margin-118.56% Return on EquityN/A Return on Assets-14.98% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$51.64 million Price / Sales14.04 Cash FlowN/A Price / Cash FlowN/A Book Value($4.59) per share Price / Book-2.34Miscellaneous Outstanding Shares67,366,000Free Float64,132,000Market Cap$724.86 million OptionableOptionable Beta0.51 Key ExecutivesRick E. WinninghamChairman & Chief Executive OfficerAndrew Asa HindmanChief Financial Officer & Senior Vice PresidentVijay SabesanSenior Vice President-Technical OperationsPhilip D. WorboysSenior VP-Research & Translational ScienceBradford J. ShaferSecretary, Executive VP & General CounselKey CompetitorsAmarinNASDAQ:AMRNPOINT Biopharma GlobalNASDAQ:PNTBelite BioNASDAQ:BLTESummit TherapeuticsNASDAQ:SMMTAnaptysBioNASDAQ:ANABView All CompetitorsInsiders & InstitutionsStrs OhioBought 16,300 shares on 1/26/2023Ownership: 0.024%Allspring Global Investments Holdings LLCSold 5,282 shares on 1/23/2023Ownership: 0.023%Palliser Capital UK LtdBought 97,100 shares on 1/17/2023Ownership: 0.144%Rick E WinninghamSold 50,000 sharesTotal: $559,500.00 ($11.19/share)Bank of New York Mellon CorpBought 23,555 shares on 12/8/2022Ownership: 0.305%View All Insider TransactionsView All Institutional Transactions TBPH Stock - Frequently Asked Questions Should I buy or sell Theravance Biopharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares. View TBPH analyst ratings or view top-rated stocks. What is Theravance Biopharma's stock price forecast for 2023? 3 analysts have issued 1-year price objectives for Theravance Biopharma's stock. Their TBPH share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price. View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts. How have TBPH shares performed in 2023? Theravance Biopharma's stock was trading at $11.22 at the beginning of the year. Since then, TBPH stock has decreased by 4.2% and is now trading at $10.75. View the best growth stocks for 2023 here. When is Theravance Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our TBPH earnings forecast. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its quarterly earnings data on Monday, November, 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The biopharmaceutical company earned $12.45 million during the quarter, compared to analysts' expectations of $19.09 million. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX). What is Theravance Biopharma's stock symbol? Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH." Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Palliser Capital UK Ltd (0.14%), Strs Ohio (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Theravance Biopharma's stock price today? One share of TBPH stock can currently be purchased for approximately $10.75. How much money does Theravance Biopharma make? Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $724.23 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or $11.26 on an earnings per share basis. How many employees does Theravance Biopharma have? The company employs 359 workers across the globe. How can I contact Theravance Biopharma? Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com. This page (NASDAQ:TBPH) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.